The biopharmaceutical company Oryzon Genomics, member of CataloniaBio, has received an injection of capital of 18.2 million euros from a group of international investors, mostly from the US. The capital increase will be mainly used to finance its research and development of clinical  pipeline candidates. As Oryzon's CEO Carlos Buesa explains: "The positive evolution of our clinical trials and this additional funding strengthens the company to further advance the achievement of significant milestones in the development of our drugs”.

With this capital increase the laboratory also wants to join international institutional investors, specialized in the pharmaceutical industry, as a permanent shareholders of Oryzon, according to the El Economista.

Photo: Carlos Buesa, CEO of Oryzon Genomics. © Oryzon.

More information on the website of Oryzon